Breakthrough pulmonary Aspergillus fumigatus infection with multiple triazole resistance in a Spanish patient with chronic myeloid leukemia

Revista Iberoamericana de Micologia

Volumn 30, Issue 1, 2013, Pages 64-68

  Mellado, Emilia ^a   De La Camara, Rafael ^b   Buendía, Buenaventura ^b   Rodriguez Tudela, Juan L ^a   Cuenca Estrella, Manuel ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Aspergillus fumigatus; Azole resistance; Case report; Cyp51A

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; HISTIDINE; ITRACONAZOLE; LYSINE; MICAFUNGIN; POSACONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLOSIS; BREAKTHROUGH INVASIVE PULMONARY ASPERGILLOSIS; CASE REPORT; CHRONIC DRUG ADMINISTRATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYP51A GENE; FUNGAL GENE; FUNGAL STRAIN; FUNGUS CULTURE; FUNGUS ISOLATION; GENE MUTATION; GRAFT VERSUS HOST REACTION; HUMAN; IN VITRO STUDY; LUNG CAVITATION; LUNG INFECTION; LUNG LAVAGE; MULTIDRUG RESISTANCE; NONHUMAN; SPAIN; STRAIN DIFFERENCE; TANDEM REPEAT;

ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPERGILLUS FUMIGATUS; COMBINED MODALITY THERAPY; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, MULTIPLE, FUNGAL; ECHINOCANDINS; FATAL OUTCOME; FEMALE; FUNGAL PROTEINS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; POINT MUTATION; POSTOPERATIVE COMPLICATIONS; PULMONARY ASPERGILLOSIS; RECURRENCE; SPAIN; SPECIES SPECIFICITY; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TRIAZOLES;

ASPERGILLUS FUMIGATUS;

EID: 84872824745     PISSN: 11301406     EISSN: 21739188     Source Type: Journal    
DOI: 10.1016/j.riam.2012.09.002     Document Type: Article

References (30)

1. de Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821.
2. Cuenca-Estrella M., Gomez-Lopez A., Mellado E., Monzon A., Buitrago M.J., Rodriguez-Tudela J.L. Analysis of the activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and moulds. Antimicrob Agents Chemother 2009, 53:2192-2195.
3. Alcazar-Fuoli L., Mellado E., Alastruey-Izquierdo A., Cuenca-Estrella M., Rodriguez-Tudela J.L. Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob Agents Chemother 2008, 52:1244-1251.
4. Balajee S.A., Borman A.M., Brandt M.E., Cano J., Cuenca-Estrella M., Dannaoui E., et al. Sequence-based identification of Aspergillus, Fusarium, and mucorales species in the clinical mycology laboratory: where are we and where should we go from here?. J Clin Microbiol 2009, 47:877-884.
5. EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin Microbiol Infect 2008, 14:982-984. Subcommittee on antifungal susceptibility testing (AFST) of the ESCMID European committee for antimicrobial susceptibility testing (EUCAST).
6. Cuenca-Estrella M., Gomez-Lopez A., Mellado E., Buitrago M.J., Monzon A., Rodriguez-Tudela J.L. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006, 50:917-921.
7. Gomez-Lopez A., Garcia-Effron G., Mellado E., Monzon A., Rodriguez-Tudela J.L., Cuenca-Estrella M. In vitro activities of three licensed antifungal agents against Spanish clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2003, 47:3085-3088.
8. Rodriguez-Tudela J.L., Alcazar-Fuoli L., Mellado E., Alastruey-Izquierdo A., Monzon A., Cuenca-Estrella M. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother 2008, 52:2468-2472.
9. Rodriguez-Tudela J.L., Alcazar-Fuoli L., Alastruey-Izquierdo A., Monzon A., Mellado E., Cuenca-Estrella M. Time of incubation for antifungal susceptibility testing of Aspergillus fumigatus: can MIC values be obtained at 24 hours?. Antimicrob Agents Chemother 2007, 51:4502-4504.
10. Alcazar-Fuoli L., Mellado E., Cuenca-Estrella M., Sanglard D. Probing the role of point mutations in the cyp51A gene from Aspergillus fumigatus in the model yeast Saccharomyces cerevisiae. Med Mycol 2011, 49:276-284.
11. Diaz-Guerra T.M., Mellado E., Cuenca-Estrella M., Rodriguez-Tudela J.L. A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 2003, 47:1120-1124.
12. Mellado E., Diaz-Guerra T.M., Cuenca-Estrella M., Rodriguez-Tudela J.L. Identification of two different 14-alpha sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species. J Clin Microbiol 2001, 39:2431-2438.
13. Mellado E., Garcia-Effron G., Alcazar-Fuoli L., Cuenca-Estrella M., Rodriguez-Tudela J.L. Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother 2004, 48:2747-2750.
14. Mellado E., Garcia-Effron G., Alcazar-Fuoli L., Melchers W.J., Verweij P.E., Cuenca-Estrella M., et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 2007, 51:1897-1904.
15. Balajee S.A., Tay S.T., Lasker B.A., Hurst S.F., Rooney A.P. Characterization of a novel gene for strain typing reveals substructuring of Aspergillus fumigatus across North America. Eukaryot Cell 2007, 6:1392-1399.
16. Hurst S.F., Kidd S.E., Morrissey C.O., Snelders E., Melchers W.J., Castelli M.V., et al. Interlaboratory reproducibility of a single-locus sequence-based method for strain typing of Aspergillus fumigatus. J Clin Microbiol 2009, 47:1562-1564.
17. Klaassen C.H., de Valk H.A., Balajee S.A., Meis J.F. Utility of CSP typing to sub-type clinical Aspergillus fumigatus isolates and proposal for a new CSP type nomenclature. J Microbiol Methods 2009, 77:292-296.
18. Escribano P., Recio S., Pelaez T., Bouza E., Guinea J. Aspergillus fumigatus strains with mutations in the cyp51A gene do not always show phenotypic resistance to itraconazole, voriconazole, or posaconazole. Antimicrob Agents Chemother 2011, 55:2460-2462.
19. Bellete B., Raberin H., Morel J., Flori P., Hafid J., Manhsung R.T. Acquired resistance to voriconazole and itraconazole in a patient with pulmonary aspergilloma. Med Mycol 2010, 48:197-200.
20. Denning D.W., Park S., Lass-Florl C., Fraczek M.G., Kirwan M., Gore R., et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 2011, 52:1123-1129.
21. Howard S.J., Pasqualotto A.C., Denning D.W. Azole resistance in allergic bronchopulmonary aspergillosis and Aspergillus bronchitis. Clin Microbiol Infect 2010, 16:683-688.
22. Verweij P.E., Mellado E., Melchers W.J. Multiple-triazole-resistant aspergillosis. N Engl J Med 2007, 356:1481-1483.
23. Cuenca-Estrella M., Gomez-Lopez A., Garcia-Effron G., Alcazar-Fuoli L., Mellado E., Buitrago M.J., et al. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob Agents Chemother 2005, 49:1232-1235.
24. Snelders E., van der Lee H.A., Kuijpers J., Rijs A.J., Varga J., Samson R.A., et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 2008, 5:e219.
25. Verweij P.E., Snelders E., Kema G.H., Mellado E., Melchers W.J. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?. Lancet Infect Dis 2009, 9:789-795.
26. Hamamoto H., Hasegawa K., Nakaune R., Lee Y.J., Makizumi Y., Akutsu K., et al. Tandem repeat of a transcriptional enhancer upstream of the sterol 14alpha-demethylase gene (CYP51) in Penicillium digitatum. Appl Environ Microbiol 2000, 66:3421-3426.
27. Ma Z., Proffe T.J., Jacobs J.L., Sundin G.W. Overexpression of the 14alpha-demethylase target gene (CYP51) mediates fungicide resistance in Blumeriella jaapii. Appl Environ Microbiol 2006, 72:2581-2585.
28. Lockhart S.R., Frade J.P., Etienne K.A., Pfaller M.A., Diekema D.J., Balajee S.A. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob Agents Chemother 2011, 55:4465-4468.
29. Mortensen K.L., Jensen R.H., Johansen H.K., Skov M., Pressler T., Howard S.J., et al. Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on Aspergillus fumigatus azole resistance. J Clin Microbiol 2011, 49:2243-2251.
30. Mortensen K.L., Mellado E., Lass-Florl C., Rodriguez-Tudela J.L., Johansen H.K., Arendrup M.C. Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. Antimicrob Agents Chemother 2010, 54:4545-4549.